Plantar Eschar and a Stable Heel Eschar in a Neuropathic Diabetic Foot: Two Different Debridement Decisions
Mr. T is 61 with type 2 diabetes (A1C 9.4%) and peripheral neuropathy; he has never had revascularization. Over the plantar first metatarsal head of the right foot is a 3.0 x 2.5 cm ulcer, 0.4 cm deep, with a thick dry black eschar covering about 60% of the base and a rim of hyperkeratotic callus. The right lateral heel has a separate 2 cm dry, intact black eschar with no drainage, no erythema, and no fluctuance; it has been unchanged for at least four months. Pedal pulses are 1+ and symmetric, right ABI is 0.95, and there is no warmth, purulent drainage, or fever. He walks indoors barefoot and his shoes have worn-out insoles.
1. Which of the two eschars should be debrided, which should be left alone, and what is the reasoning in each case?
Read the worked answer
Forefoot ulcer: debride (by a trained clinician, with an order).
- Perfusion is adequate (ABI 0.95, palpable pulses), so debridement will not create an ischemic wound.
- The dry eschar hides depth and any underlying abscess or tendon/bone involvement, and it blocks assessment and healing.
- The surrounding callus is a mechanical load problem: thickened callus over a metatarsal head concentrates pressure and keeps the ulcer open. Debriding callus is a core offloading intervention, not cosmetic.
- Plan: conservative sharp debridement of callus and eschar to a clean, bleeding base, with hemostasis available; reassess depth and probe for bone after debridement. If bone is reachable, treat as possible osteomyelitis and refer.
Heel eschar: leave intact and protect.
- It is dry, intact, non-fluctuant, non-draining, and unchanged for months - a "stable heel eschar."
- Intact dry eschar acts as a natural biologic cover; removing it in a patient with neuropathy and diabetes risks converting a closed, stable lesion into an open portal for infection and into a wound that is very hard to heal.
- Management: complete offloading of the heel (float the heel with pillows under the calves or a heel suspension device), keep it dry, inspect at every visit, and document stability (size, appearance, absence of drainage/erythema).
- Escalate urgently if drainage, erythema, warmth, fluctuance, or pain develops - that converts it from a stable eschar to a drainage/infection problem requiring medical and possibly surgical evaluation.
General rule: debridement decisions hinge on perfusion, infection, and the presence of a healing barrier - not on the color of the tissue alone. With an ABI below roughly 0.5, absent pedal pulses, or untrained staff, sharp debridement of an ischemic foot is not the home-care answer.
2. Two weeks after debridement the base is clean granulation tissue with moderate exudate, and the periwound skin is macerated. What local management and offloading plan do you put in place, and why in that order?
Read the worked answer
Offloading first - it outranks dressing choice. A plantar neuropathic ulcer will not close under continued walking pressure no matter how good the dressing is.
- Gold standard: total contact cast (TCC) or an irremovable walker, provided there is no untreated infection, no severe ischemia, and the patient consents and can be monitored.
- If a TCC is not feasible, use a removable cast walker made irremovable ("instant TCC") or a prefabricated pneumatic walker; a purely removable device is usually taken off, and adherence must be verified, not assumed.
- Absolute rule: no barefoot walking, including indoors at night. Provide the walker for all steps and address footwear (therapeutic/extra-depth shoes with custom insoles once healed).
Moisture balance (TIME - manage exudate, protect edges):
- Moderate exudate with a granulating base: a hydrofiber/gelling fiber or a foam, or an alginate if bleeding is a concern; a perforated non-adherent contact layer under foam is acceptable.
- Macerated periwound: cleanse, dry gently, and apply a barrier film or zinc-based protectant to the peri-wound skin; avoid adhesives that strip fragile skin - use silicone-bordered products.
- Change frequency based on strike-through, typically 2-3 times weekly, and taper to a less absorbent dressing as exudate falls.
Supporting measures: continue callus debridement at edges, weekly measurement with a consistent method, glucose control (A1C 9.4% impairs healing), and inspect the contralateral foot and heels at every visit. Avoid whirlpool and antiseptic soaking; do not use astringents or heat.
3. At the 4-week mark the ulcer's dimensions are unchanged. What should this trigger, and what would make you change the diagnosis rather than just the dressing?
Read the worked answer
A plantar neuropathic ulcer that has not reduced in size by roughly 4 weeks of appropriate care is a failure of the plan, not a reason to try a new dressing at random. Work through the causes systematically:
1. Offloading adherence (most common). Ask, don't assume: does he wear the device at home? Consider an irremovable device, or check for wear patterns/step counts. 2. Perfusion. ABI 0.95 today does not guarantee it next month, especially with diabetes and medial calcinosis. Repeat vascular assessment; toe pressures or TcPO2 are more reliable in diabetes. Refer to vascular surgery if perfusion is borderline or rest pain/claudication appears. 3. Infection and bone involvement. Probe for bone at every visit; new foul odor, friable tissue, sinus tract, or an ulcer that will not shrink should prompt imaging for osteomyelitis. 4. Mechanical/structural. Unresolved callus, deformity, or a worn-out device. 5. Systemic factors. Glucose control, nutrition, edema, smoking, renal disease. 6. Wrong diagnosis. If the wound is atypical (rolled edges, violaceous border, unusual location, no response to good care), biopsy to rule out malignancy, pyoderma, or another vasculopathy rather than escalating dressings.
When to change the diagnosis: if the ulcer is exquisitely painful, has a punched-out appearance, is on the dorsum or lateral foot rather than a pressure point, or the foot is cold and pulseless, stop treating it as a neuropathic ulcer. Refer for arterial evaluation - advanced therapies (negative pressure, cellular/amniotic products, growth factors) are only appropriate after offloading, perfusion, and infection have been addressed, and are not a substitute for them.